Top

Published in:

01-06-2010 | Brief Article

Quantitative Assessment of the Hepatic Metabolic Volume Product in Patients with Diffuse Hepatic Steatosis and Normal Controls Through Use of FDG-PET and MR Imaging: A Novel Concept

Authors: Gonca G. Bural, Drew A. Torigian, Anne Burke, Mohamed Houseni, Khaled Alkhawaldeh, Andrew Cucchiara, Sandip Basu, Abass Alavi

Published in: Molecular Imaging and Biology | Issue 3/2010

Abstract

Aims and Objectives

The aim of this study was to compare hepatic standardized uptake values (SUVs) and hepatic metabolic volumetric products (HMVP) between patients of diffuse hepatic steatosis and control subjects with normal livers.

Materials and Methods

Twenty-seven subjects were included in the study (13 men and 14 women; age range, 34–72 years). All had 18F-2-fluoro-2-D-deoxyglucose-positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI) scans with an interscan interval of 0–5 months. Twelve of 27 subjects had diffuse hepatic steatosis on MRI. The remaining 15 were selected as age-matched controls based on normal liver parenchyma on MRI. Mean and maximum hepatic SUVs were calculated for both patient groups on FDG-PET images. Hepatic volumes were measured from MRI. HMVP in each subject was subsequently calculated by multiplication of hepatic volume by mean hepatic SUV. HMVPs as well as mean and maximum hepatic SUVs were compared between the two study groups.

Results

HMVPs, mean hepatic SUVs, and maximum hepatic SUVs were greater (statistically significant, p < 0.05) in subjects with diffuse hepatic steatosis compared to those in the control group.

Conclusion

The increase in HMVP is the result of increased hepatic metabolic activity likely related to the diffuse hepatic steatosis. The active inflammatory process related to the diffuse hepatic steatosis is the probable explanation for the increase in hepatic metabolic activity on FDG-PET study.

Wanless IR, Shiota K (2004) The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 24:99–106CrossRefPubMed

Lalor PF, Faint J, Aarbodem Y, Hubscher SG et al (2007) The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 27:173–193CrossRefPubMed

Harrison SA, Kadakia S, Lang KA et al (2002) Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 97:2714–2724PubMed

McCullough AJ (2004) The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8:521–533CrossRefPubMed

Spahr L, Hadengue A (2005) Alcoholic and nonalcoholic steatohepatitis: the same disease! II. Management. Rev Med Suisse 7(1):2032–2034

Saadeh S, Younossi ZM, Remer EM et al (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745–750CrossRefPubMed

van Hoek B (2004) Non-alcoholic fatty liver disease: a brief review. Scand J Gastroenterol 241:56–59CrossRef

El-Haddad G, Zhuang H, Gupta N et al (2004) Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34:313–329CrossRefPubMed

Zhuang H, Alavi A (2002) 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32:47–59CrossRefPubMed

10.

Siegelman ES, Rosen MA (2001) Imaging of hepatic steatosis. Semin Liver Dis 21:71–80CrossRefPubMed

11.

Itai Y, Saida Y (2002) Pitfalls in liver imaging. Eur Radiol 12:1162–1174CrossRefPubMed

12.

Mortele KJ, Ros PR (2001) Imaging of diffuse liver disease. Semin Liver Dis 21:195–212CrossRefPubMed

13.

Siegelman ES (1997) MR imaging of diffuse liver disease. Hepatic fat and iron. Magn Reson Imaging Clin N Am 5:347–365PubMed

14.

Choi S, Diehl AM (2005) Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 21:702–707CrossRefPubMed

15.

Day CP, James OF (2005) Steatohepatitis: a tale of two “hits”? Curr Opin Gastroenterol 21:702–707CrossRef

16.

Haque M, Sanyal AJ (2002) The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 16:709–731CrossRefPubMed

17.

Feldstein AE, Canbay A, Angulo P et al (2003) Hepatocyte apoptosis and fas expression are prominent features of human non-alcoholic steatohepatitis. Gastroenterology 125:437–443CrossRefPubMed

18.

Feldstein AE, Werneburg NW, Canbay A et al (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40:185–194CrossRefPubMed

19.

Valenti L, Fracanzani AL, Dongiovanni P et al (2002) Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122:274–280CrossRefPubMed

20.

Wigg AJ, Roberts-Thomson IC, Dymock RB et al (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206–211CrossRefPubMed

21.

Hui JM, Hodge A, Farrell GC et al (2004) Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40(1):46–54CrossRefPubMed

22.

McCuskey RS, Ito Y, Robertson GR et al (2004) Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 40:386–393CrossRefPubMed

23.

Zhuang H, Yu JQ, Alavi A (2005) Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 43:121–134CrossRefPubMed

24.

Busetto L, Tregnaghi A, De Marchi F et al (2002) Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 10:408–411CrossRefPubMed

25.

Tchelepi H, Ralls PW, Radin R, Grant E (2002) Sonography of diffuse liver disease. J Ultrasound Med 21:1023–1032PubMed

26.

Nomura F, Ohnishi K, Ochiai T, Okuda K (1987) Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 162:845–847PubMed

27.

Fishbein MH, Gardner KG, Potter CJ et al (1997) Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 15:287–293CrossRefPubMed

28.

Qayyum A, Goh JS, Kakar S et al (2005) Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques—initial experience. Radiology 237:507–511CrossRefPubMed

29.

Lupsor M, Badea R (2005) Imaging diagnosis and quantification of hepatic steatosis: is it an accepted alternative to needle biopsy? Rom J Gastroenterol 14:419–425PubMed

30.

Chave G, Milot L, Pilleul F (2005) Out of phase magnetic resonance imaging and liver applications. J Radiol 86(9 Pt 1):993–997CrossRefPubMed

31.

Das K, Kar P (2005) Non-alcoholic steatohepatitis. J Assoc Phys India 53:195–199

32.

Fishbein M, Mogren J, Mogren C et al (2005) Undetected hepatomegaly in obese children by primary care physicians: a pitfall in the diagnosis of pediatric nonalcoholic fatty liver disease. Clin Pediatr (Phila) 44:135–141CrossRef

33.

Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(2 Suppl 1):S99–S112CrossRefPubMed

34.

Yki-Järvinen H (2005) Fat in the liver and insulin resistance. Ann Med 37:347–356CrossRefPubMed

35.

Bugianesi E, Zannoni C, Vanni E et al (2004) Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 36:165–173CrossRefPubMed

36.

Burke A, Lucey MR (2004) Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 4:686–693CrossRefPubMed

Title: Quantitative Assessment of the Hepatic Metabolic Volume Product in Patients with Diffuse Hepatic Steatosis and Normal Controls Through Use of FDG-PET and MR Imaging: A Novel Concept
Authors: Gonca G. Bural
Drew A. Torigian
Anne Burke
Mohamed Houseni
Khaled Alkhawaldeh
Andrew Cucchiara
Sandip Basu
Abass Alavi
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 3/2010
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-009-0258-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative Assessment of the Hepatic Metabolic Volume Product in Patients with Diffuse Hepatic Steatosis and Normal Controls Through Use of FDG-PET and MR Imaging: A Novel Concept

Abstract

Aims and Objectives

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims and Objectives

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2010

Erratum to: The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT

Molecular Imaging of the Translocator Protein (TSPO) in a Pre-Clinical Model of Breast Cancer

Two-Step In Vivo Tumor Targeting by Biotin-Conjugated Antibodies and Superparamagnetic Nanoparticles Assessed by Magnetic Resonance Imaging at 1.5 T

In Vivo Fluorescence Imaging is Well-Suited for the Monitoring of Adenovirus Directed Transgene Expression in Living Organisms

Development and Validation of a Monte Carlo Simulation Tool for Multi-Pinhole SPECT

Feasibility of Template-Guided Attenuation Correction in Cat Brain PET Imaging